Strategies for Targeting Tumors and Tumor Vasculature for Cancer Therapy

Advances in Genetics

Volumn 69, Issue C, 2010, Pages 135-152

  Sreeramoju, Prashanth ^a   Libutti, Steven K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; NANOPARTICLE;

DRUG DELIVERY SYSTEM; GENE THERAPY; GENE VECTOR; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PERFUSION; REVIEW; SIGNAL TRANSDUCTION;

DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS; PERFUSION; SIGNAL TRANSDUCTION;

EID: 77956149322     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(10)69015-3     Document Type: Book

References (65)

1. Alexander H.R., Bartlett D.L., Libutti S.K., Fraker D.L., Moser T., Rosenberg S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Surg. Oncol. 1998, 16:1479-1489.
2. Alexander H.R., Libutti S.K., Pingpank J.F., et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann. Surg. Oncol. 2005, 12:138-144.
3. Barker E., Planelles V. Vectors derived from the human immunodeficiency virus, HIV-1. Front. Biosci. 2003, 8:491-510.
4. Benckhuijsen C., Kroon B.B., van Geel A.N., Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur. J. Surg. Oncol. 1988, 14:157-163.
5. Bergelson J.M., Cunningham J.A., Droguett G., et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
6. Chandler J., Robinson N., Whiting K. Handling false signals in gold-based tests. I.V.D Technol. 2001, 72:34-35.
7. Chang D., Chiu C., Kuo S., Lin W., Lo A., Wang Y., Li Pi., Wu H. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 2009, 284(19):12905-12916.
8. Chen Q.R., Kumar D., Stass S.A., Mixson A.J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59:3308-3312.
9. Creech O., Krementz E.T., Ryan R.F., Winblad J.N. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 1958, 148:616-632.
10. De Palma M., Mazzieri R., Politi L.S., Pucci F., Zonari E., Sitia G., et al. Tumor targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14:299-311.
11. Eggermont A.M., Schraffordt Koops H., Klausner J.M., Kroon B.B., Schlag P.M., Lienard D., van Geel A.N., Hoekstra H.J., Meller I., Nieweg O.E., Kettelhack C., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 1996, 224:756-764.
12. Eggermont A.M., Schraffordt Koops H., Lienard D., Kroon B.B., van Geel A.N., Hoekstra H.J., Lejeune F.J. Isolated limb perfusion with high- dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonre- sectable extremity soft tissue sarcomas: A multi-center trial. J. Clin. Oncol. 1996, 14:2653-2665.
13. Eggermont A.M., Schraffordt Koops H., Klausner J.M., Schlag P.M., Lienard D., Kroon B.B.R., Gustafson P., Steinmann G., Clarke J., Lejeune F. Limb salvage by isolated limb perfusion (ILP) with TNF and melphalan in patients with locally advanced soft tissue sarcomas: Outcome of 270 ILPs in 246 patients. Proc. Am. Soc. Clin. Oncol. 1999, 18:2067.
14. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
15. Faraday M. Experimental relations of gold (and other metals) to light. Philos. Trans. R. Soc. London 1857, 14:145-181.
16. Feldman A.L., Restifo N.P., Alexander H.R., Bartlett D.L., Hwu P., Seth P., Libutti S.K. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 2000, 60:1503-1506.
17. Furman W.I., Strother D., McClain K., Bell B., Leventhol B., Pratt C.B. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A pediatric oncology group study. J. Clin. Oncol. 1993, 11:2205-2210.
18. Grunhagen D.J., Brunstein F., Graveland W.J., van Geel A.N., de Wilt J.H., Eggermont A.M. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann. Surg. Oncol. 2005, 12:473-479.
19. Grünhagen D.J., de Wilt J.H., Graveland W.J., Verhoef C., van Geel A.N., Eggermont A.M. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006, 106:1776-1784.
20. Gutman M., Inbar M., Lev-Shlush D., Abu-Abid S., Mozes M., Chaitchik S., Meller I., Klausner J.M. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997, 79:1129-1137.
21. Hagen T.L., Eggermont A.M. Solid tumor therapy: Manipulation of the vasculature with TNF. Technol. Cancer Res. Treat. 2003, 2:195-203.
22. Hajitou A., Range L.R., Trepel M., et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat. Protoc. 2007, 2:523-531.
23. Hill S., Fawcett W.J., Sheldon J., Soni N., Williams T., Thomas J.M. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br. J. Surg. 1993, 80:995-997.
24. Kaner R.J., Baird A., Manusukhani A., et al. Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type-1. Science 1990, 248:1410-1413.
25. Kashiwakura Y., Tamayose K., Iwabuchi K., et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 2005, 79:609-614.
26. Li Z., Düllmann J., Schiedlmeier B., Schmidt M., Stocking C., Wahlers A., Ostertag W., Kühlcke K., Fehse B., Baum C., et al. Murine Leukemia Induced by Retroviral Gene Marking. Science 2002, 296:497.
27. Libutti S.K., Bartlett D.L., Fraker D.L., et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J. Am. Coll. Surg. 2000, 191:519-530.
28. Liu Y., Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene. Cancer Gene Therapy 2006, 13:845-855.
29. Liu L., Anderson W.F., Beart R.W., Gordon E.M., Hall F.L. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J. Virol. 2000, 74:5320-5328.
30. Mavira G., Harrington K.J., Marshall C.J., Porter C.D. In vivo efficacy of HSV-TK transcriptionally targeted to the tumor vasculature is augmented by combination with cytotoxic chemotherapy. J. Gene Med. 2005, 7:263-275.
31. McCart J.A., Ward J.M., Lee J., Hu Y., Alexander H.R., Libutti S.K., Moss B., Bartlett D.L. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001, 61(24):8751-8757.
32. McCart J.A., Mehta N., Scollard D., Reilly R.M., Carrasquillo J.A., Tang N., Deng H., Miller M., Xu H., Libutti S.K., Alexander H.R., Bartlett D.L. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: Molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 2004, 10(3):553-561.
33. Miao N., Pingpank J.K., Alexander R.H., Steinberg S.M., Beresneva T., Quezado Z. Percutaneous hepatic perfusion in patients with metastatic liver cancer: Anesthetic, hemodynamic, and metabolic considerations. Ann. Surg. Oncol. 2008, 15(3):815-823.
34. Miller A.D. Retroviral vectors. Curr. Top. Microbiol. Immunol. 1992, 158:1-24.
35. Mirkin C.A., Letsinger R.L., Mucic R.C., Storhoff J.J. A DNA based method for rationally assembling nanoparticles into macroscopic materials. Nature 1996, 382:607-609.
36. National Center for Health Statistics and Centers for Disease Control and Prevention (2006). US Mortality Public Use Data Tape 2003.
37. Netti P.A., Hamberg L.M., Babich J.W., Kierstia D., Graham W., Hunter G.J., Wolf G.L., Fischnan A., Boucher Y., Jain R.K. Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA 1999, 96:3137-3142.
38. Nguyen J.T., Wu P., Clouse M.E., Hlatky L., Terwilliger E.F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 1998, 8:5673-5677.
39. Nicklin S.A., Buening H., Dishart K., et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 2001, 4:174-181.
40. Okayasu I., Hatakeyama S., Yoshida T., Yoshimatsu S., Tsuruta K., Miyamoto H., et al. Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery. Am. J. Clin. Pathol. 1988, 90:536-544.
41. Paciotti G.F., Myer L., Weinreich D., Goia D., Pavel N., McLaughlin R.E., Tamarkin L. Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004, 11(3):169-183.
42. Paoloni M.C., Tandle A., Mazcko C., Arap W., Khanna C., Pasqualini R., Libutti S.K., et al. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting ofTNFα to cancer vasculature. PLoS One 2009, 4(3):e4972.
43. Pingpank J.F., Libutti S.K., Chang R., Wood B.J., Neeman Ziv, Kam Anthony, W., Figg William, D., Geoffrey D., Alexander H.R., et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J. Clin. Oncol. 2005, 23:3465-3474.
44. Powell A.C., Paciotti G.F., Libutti S.K. Colloidal gold: A novel nanoparticles for targeted cancer therapeutics. Methods Mol. Boil. 2010, 624:375-384.
45. Rodolfo M., Cato E.M., Soldati S., Ceruti R., Asioli M., Scanziani E., Vezzoni P., Parmiani G., Sacco M.G. Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther. 2001, 8:491-496.
46. Rofstad E.K., Siv H., Tunheim Berit, M., Bjørn A., Graff E.F., Halsør Kristin, N., Galappathi K. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res. 2002, 62:661-664.
47. Root S.W., Andrews G.A., Knieseley R.M., Tyor M.P. The distribution and radiation effects of intravenously administered colloidal Au198 in man. Cancer 1954, 7:856-866.
48. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., et al. Gene transfer into humans immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323:570-578.
49. Rosenberg S.A., Blaese R.M., Brenner M.K., Deisseroth A.B., Led- ley F.D., Lotze M.T., et al. Human gene marker/therapy clinical protocols. Hum. Gene. Ther. 1999, 10:3067-3123.
50. Rubin P., Levitt S.H. The response of disseminated reticulum cell sarcoma to the intravenous injection of colloidal radioactive gold. J. Nuclear Med. 1964, 5:581-594.
51. Schiller J.H., Storer B.E., Witt P.L., Alberti D., Tombes M.M.B., Arzoomanian R., Proctor R.A., McCarthy D., Brown R.R., Voss S.D., Remick S.C., Grem J.L., Borden E.C., Trump D.L. Biological and clinical effects of intravenous tumor necrosis factor-a administered three times weekly. Cancer Res. 1991, 51:1651-1658.
52. Seth P. Vector-medicated cancer gene therapy. Cancer Biol. Ther. 2005, 4(5):512-517.
53. Shichinohe T., Bochner B.H., Mizutani K., Nishida M., Hegerich-Gilliam S., Naldini L., Kasahara N. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther. 2001, 8:879-889.
54. Song W., Sun Q., Dong Z., Spencer D.M., Nunez G., Nor J.E. Antiangiogenic gene therapy: Disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector. Gene Ther. 2005, 12:320-329.
55. Stohrer M., Boucher Y., Stangassinger M., Jain R.K. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60:4251-4255.
56. Tandle A., Blazer D.G., Libutti S.K. Antiangiogenic gene therapy of cancer: Recent developments. J. Transl. Med. 2004, 2:22.
57. Tandle A., Hanna E., Lorang D., Hajitou A., Moya C., Pasqualini R., Arap W., Adem A., Straker E., Hewitt S., Libutti S.K. Tumor vasuclature-targeted delivery of tumor necrosis factor-α. Cancer 2009, 115(1):128-139.
58. Trepel M., Pasqualini E., Arap W. Screening phage-display peptide libraries for vascular-targeted peptides. Methods Enzymol. 2008, 445:88-106.
59. Varda-Bloom N., Shaish A., Gonen A., et al. Tissue- specific gene therapy directed to tumor angiogenesis. Gene Ther. 2001, 8:819-827.
60. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73:309-319.
61. Wieberdink J., Benckhuysen C., Braat R.P., van Slooten E.A., Olthuis G.A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur. J. Cancer Clin. Oncol. 1982, 18:905-910.
62. Wigmore S.J., Redhead D.N., Thomson B.N., Currie E.J., Parks R.W., Madhavan K.K., et al. Postchemoembolisation syndrome-tumour necrosis or hepatocyte injury?. Br. J. Cancer 2003, 89:1423-1427.
63. Wood R.J., Byrnes A.P., Pfaff D.W., Rabkin S.D., Charlton H.M. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther. 1994, 1:283-291.
64. Yotnda P., Chen D.H., Chiu W., Piedra P.A., Davis A., Templeton N.S., Brenner M.K. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol. Ther. 2002, 5:233-241.
65. Zhang X.Y., Luck J., Derhirst M.W., Fan Yuan F. Interstitial hydraulic conductivity in a fibrosarcoma. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H2726-H2734.